Patents by Inventor Maobo Wu

Maobo Wu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Long-acting recombinant human follicle-stimulating hormone-Fc fusion protein
    Patent number: 10023624
    Abstract: Recombinant Fc fusion proteins of human follicle-stimulating hormone (hFSH) with in vivo biological activities comparable to those of human follicle-stimulating hormone are disclosed. A recombinant hFSH-Fc fusion protein comprises ? subunit of hFSH (hFSH ?), CTP, ? subunit of hFSH (hFSH ?), a flexible peptide linker, and human IgG2 Fc variant (vIgG2Fc). A method is also disclosed to make such fusion proteins at good expression levels. These recombinant hFSH-Fc fusion proteins of the present disclosure exhibit sufficient biological activities and prolonged plasma half-lives, leading to improved pharmacokinetics and pharmacodynamics. Thus, a lower dosage may be used and/or better or different therapeutic efficacies with less side effects may be achieved. A method for the application of the recombinant hFSH-Fc fusion proteins in the treatment and/or prevention of human infertility is also disclosed.
    Type: Grant
    Filed: August 22, 2014
    Date of Patent: July 17, 2018
    Assignee: UnicoHealth Co. Ltd.
    Inventors: Yongmin Hou, Qiang Li, Maobo Wu, Sha Liao, Yujie Zhang, Zhenqi Xu
  • LONG-ACTING RECOMBINANT HUMAN FOLLICLE-STIMULATING HORMONE-FC FUSION PROTEIN
    Publication number: 20170174736
    Abstract: Recombinant Fc fusion proteins of human follicle-stimulating hormone (hFSH) with in vivo biological activities comparable to those of human follicle-stimulating hormone are disclosed. A recombinant hFSH-Fc fusion protein comprises ? subunit of hFSH (hFSH ?), CTP, ? subunit of hFSH (hFSH ?), a flexible peptide linker, and human IgG2 Fe variant (vIgG2Fc). A method is also disclosed to make such fusion proteins at good expression levels. These recombinant hFSH-Fc fusion proteins of the present disclosure exhibit sufficient biological activities and prolonged plasma half-lives, leading to improved pharmacokinetics and pharmacodynamics. Thus, a lower dosage may be used and/or better or different therapeutic efficacies with less side effects may be achieved. A method for the application of the recombinant hFSH-Fc fusion proteins in the treatment and/or prevention of human infertility is also disclosed.
    Type: Application
    Filed: August 22, 2014
    Publication date: June 22, 2017
    Inventors: Yongmin Hou, Qiang Li, Maobo Wu, Sha Liao, Yujie Zhang, Zhenqi Xu